文献速递免疫规划

重组Erns-E2蛋白疫苗联合MF59与CPG-ODN佐剂促进针对牛病毒性腹泻病毒感染的T细胞免疫

Recombinant Erns-E2 protein vaccine formulated with MF59 and CPG-ODN promotes T cell immunity against bovine viral diarrhea virus infection.
PubMed 文献 · Vaccine · 2020-04-10

本研究制备含MF59和CPG-ODN佐剂的重组Erns-E2蛋白疫苗,并将重组质粒pET32a-Erns-E2转化BL21(DE3)细胞生产Erns-E2蛋白。用MF59和CPG-ODN佐剂化的重组Erns-E2蛋白、E2蛋白或Erns蛋白分别免疫小鼠,免疫后以BVDV BJ175170株攻击。所有佐剂化疫苗均诱发了可检测的体液和细胞免疫应答,Erns-E2免疫小鼠的BVDV特异性抗体滴度和血清IL-4水平高于Erns或E2免疫小鼠,Erns-E2疫苗诱导的CD4+IFN-γ+、CD8+IFN-γ+ T细胞和CD3+TNF-α+ T细胞百分比高于其他疫苗。

要点

  • 含MF59和CPG-ODN佐剂的重组Erns-E2蛋白疫苗在小鼠中诱导了可检测的体液和细胞免疫应答。
  • Erns-E2免疫小鼠的BVDV特异性抗体滴度和血清IL-4水平高于Erns或E2免疫小鼠,CD4+IFN-γ+、CD8+IFN-γ+和CD3+TNF-α+ T细胞百分比也更高。
  • Erns-E2免疫小鼠较对照和其他疫苗组病毒血症减轻、病理变化轻微,作者认为该疫苗-佐剂组合可作为对抗BVDV的疫苗策略。

核心结论

  • 作者认为,使用含MF59和CPG-ODN佐剂的重组Erns-E2蛋白疫苗可增强T细胞应答和病毒控制,值得将该Erns-E2蛋白疫苗-佐剂组合作为对抗BVDV的疫苗策略。

研究设计与样本

  • 本研究构建重组质粒pET32a-Erns-E2并转化BL21(DE3)细胞生产Erns-E2蛋白。
  • 将MF59和CPG-ODN佐剂化的重组Erns-E2蛋白、E2蛋白或Erns蛋白分别免疫小鼠,免疫后以BVDV BJ175170株攻击小鼠,以评估疫苗-佐剂组合的免疫原性和效力。

主要发现

  • 所有佐剂化疫苗均诱发了可检测的体液和细胞免疫应答。
  • Erns-E2免疫小鼠的BVDV特异性抗体滴度及血清IL-4水平高于Erns或E2免疫小鼠。
  • Erns-E2疫苗诱导的CD4+IFN-γ+、CD8+IFN-γ+ T细胞和CD3+TNF-α+ T细胞百分比高于其他疫苗。
  • 与对照小鼠和其他疫苗免疫小鼠相比,Erns-E2免疫小鼠病毒血症减轻、病理变化轻微,获得了更多针对BVDV感染的保护效力。

临床怎么用

  • 作者认为,含MF59和CPG-ODN佐剂的重组Erns-E2蛋白疫苗-佐剂组合可作为对抗BVDV的疫苗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To obtain an effective vaccine candidate against bovine viral diarrhea virus (BVDV) disease which causes great economical loss in cattle industries, recombinant Erns-E2 protein vaccine containing MF59 and CPG-ODN adjuvants was prepared and assessed in this study. The recombinant plasmid (pET32a-Erns-E2) was constructed and transformed into BL21 (DE3) cells to produce Erns-E2 protein. We immunized mice with the MF59-and CPG-ODN-adjuvanted recombinant Erns-E2 protein, E2 protein, or Erns protein, respectively. To evaluate immunogenicity and efficacy of a vaccine-adjuvant combination, mice were challenged with BVDV BJ175170 strain after immunization. All adjuvanted vaccines elicited detectable humoral and cellular immune responses, the BVDV-specific antibody titers as well as interleukin 4 (IL-4) levels in sera of mice immunized with the recombinant Erns-E2 protein were higher than in those of mice immunized with either the recombinant Erns or E2 protein. Besides, immunization with the Erns-E2 vaccines induced higher percentage of CD4+IFN-γ+, CD8+IFN-γ+ T cells and CD3+TNF-α+ T cells compared with the other vaccines. More protective efficacy against BVDV infection was acquired in the mice treated with the recombinant Erns-E2 protein, as shown by a reduction of viremia and slight pathological changes compared with both the control mice and the other vaccinated mice. Our findings suggest that the use of the recombinant Erns-E2 protein vaccine formulated with MF59 and CPG-ODN adjuvants enhances T cell responses and viral control, which warrants the Erns-E2 protein vaccine-adjuvant combination could be as a vaccine strategy to against BVDV.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wang S, Yang G, Nie J, et al. Recombinant Erns-E2 protein vaccine formulated with MF59 and CPG-ODN promotes T cell immunity against bovine viral diarrhea virus infection. Vaccine. 2020. PMID: 32280039. doi:10.1016/j.vaccine.2020.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。